Atypical pneumonias in ICU: Legionella, Mycoplasma, Chlamydia · ICU Topics

Cinematic ICU scene of a ventilated patient with a patchy interstitial infiltrate on the chest X-ray, a urinary antigen panel and a respiratory PCR sample in the rack, a macrolide and a respiratory fluoroquinolone drawn up, clinical-blue lighting, medical educational, no faces, no text — FigureAtypical pneumonias — Mycoplasma, Chlamydia, Legionella, Coxiella — present with a patchy interstitial pattern, prominent systemic symptoms and a paucity of physical findings relative to the radiograph. Legionella is the severe ICU pathogen (hyponatraemia, diarrhoea, confusion) requiring a urinary antigen and a macrolide or fluoroquinolone. Severely ill CAP is covered empirically with a β-lactam PLUS a macrolide or respiratory fluoroquinolone until the pathogen is identified.

Educational pathophysiology of atypical pneumonia: intracellular pathogens Legionella Mycoplasma Chlamydia, alveolar and extrapulmonary toxin effects, SIADH diarrhoea confusion for Legionella, clinical-blue, no faces — FigureAtypical pathogens are intracellular — beta-lactams fail; macrolides, doxycycline and fluoroquinolones penetrate cells.

Management algorithm for severe CAP covering atypicals: beta-lactam plus macrolide or respiratory fluoroquinolone, urine Legionella antigen, respiratory PCR, step-down when pathogen known, clinical educational infographic — FigureSevere CAP empiric cover: beta-lactam + macrolide (or respiratory FQ). Confirm Legionella with urine antigen/PCR; de-escalate to pathogen-directed therapy.

Atypical pneumonia pathogens

Feature	Legionella pneumophila	Mycoplasma pneumoniae	Chlamydia psittaci	Coxiella burnetii
Severity	SEVERE (ICU common)	Mild-moderate ('walking pneumonia')	Variable	Usually mild (Q fever)
Source	Water (cooling towers, spas, showers)	Person-to-person (droplet)	Birds (parrots, pigeons — psittacosis)	Animals (cattle, sheep — Q fever)
Age	>50, smokers, immunocompromised	Young adults (5-20)	Bird owners, pet shop workers	Farmers, veterinarians
Clinical clues	GI (diarrhoea, nausea), neurological (confusion), SIADH/hyponatraemia, relative bradycardia, high fever	Dry cough, prominent extrapulmonary (haemolysis, rash, neurological, arthritis)	Dry cough, headache, splenomegaly, hepatitis	Fever, hepatitis, endocarditis
Diagnosis	Urine antigen (L. pneumophila serogroup 1), PCR, serology	PCR (throat), serology	Serology (4-fold rise)	Serology
Treatment	Levofloxacin OR azithromycin	Azithromycin OR doxycycline	Doxycycline	Doxycycline
Mortality	5-30% (higher if untreated)	<1%	1-5% (untreated 20%)	1-2%

[1]

Empiric antibiotic strategy for severe CAP (covering atypicals)

Severe CAP (ICU) — cover BOTH typical (S. pneumoniae) AND atypical pathogens
Beta-lactam + macrolide: ceftriaxone 2g IV OD + azithromycin 500mg IV OD (PREFERRED — covers typicals + atypicals)
OR Beta-lactam + fluoroquinolone: ceftriaxone + levofloxacin/moxifloxacin (if macrolide allergy)
OR fluoroquinolone monotherapy (moxifloxacin) — covers both typicals + atypicals (for non-severe only)
Add atypical cover EARLY — beta-lactams ALONE do NOT cover atypicals (Legionella, Mycoplasma, Chlamydia)
Narrow when pathogen identified — if Legionella confirmed: levofloxacin or azithromycin monotherapy
Duration: 5-7 days (CAP), 7-14 days (Legionella — longer, immunocompromised)

[1]

SAQ — Legionnaires\u2019 disease in severe community-acquired pneumonia

10 minutes · 10 marks

A 62-year-old male smoker returns from a cruise with a 4-day history of high fever (39.4°C), dry cough, confusion and profuse watery diarrhoea. On examination he is delirious, pulse 88 in sinus, BP 96/60, RR 30, SpO₂ 90% on room air with focal right lower lobe crackles. Bloods: Na⁺ 126, K⁺ 3.2, creatinine 150, ALT 110, CK 1200, WCC 14. Chest X-ray shows a dense right lower lobe consolidation. He is admitted to ICU for severe CAP.

[1]

SAQ — Mycoplasma cold-agglutinin haemolytic anaemia

10 minutes · 10 marks

A 19-year-old university student presents with a 10-day dry cough, low-grade fever and malaise. On the day of admission he notices dark urine and blue-tinged fingers after walking to hospital in the cold. Examination: pale, mildly jaundiced, acrocyanosis of the fingers, extensive bilateral crackles. Haemoglobin 68 g/L, reticulocytes 9%, unconjugated bilirubin 65, LDH 1200, haptoglobin undetectable. Chest X-ray shows patchy bilateral lower-lobe infiltrates far more extensive than the clinical picture suggests.

[1]

Clinical pearls

High-yield atypical pneumonia points for CICM/FFICM exam

'Atypical' pathogens are NOT seen on Gram stain and do NOT grow on standard culture. Legionella (intracellular, needs buffered charcoal yeast extract — BCYE agar), Mycoplasma (cell wall-deficient, needs special media), Chlamydia (intracellular). You CANNOT diagnose from sputum Gram stain. Need: urine antigen (Legionella), PCR, serology.[4] }
Beta-lactams do NOT cover atypicals. Atypicals lack typical cell wall (Mycoplasma) or are intracellular (Legionella, Chlamydia) → beta-lactams (which target cell wall synthesis) INEFFECTIVE. Need: macrolides, tetracyclines, or fluoroquinolones (which act intracellularly or on ribosomes). If CAP not responding to beta-lactam → add atypical cover.[4] }
Legionella urine antigen is the rapid diagnostic test. Detects L. pneumophila SEROGROUP 1 (causes 80-90% of Legionnaires disease). Result within hours. HIGH specificity (>95%), moderate sensitivity (70-90%). Limitation: only detects serogroup 1 (other serogroups need PCR/serology). Urine can be sent from day 1.[1] }
Legionella clinical clues ('Winawer-Clancy criteria'). (1) GI symptoms (diarrhoea, nausea, vomiting — 50%). (2) Neurological (confusion, headache — 30%). (3) SIADH (hyponatraemia — Na <130). (4) Relative bradycardia (pulse slower than expected for fever). (5) High fever (>39°C). (6) NO sputum production (dry cough). (7) Beta-lactam failure. If several present → think Legionella.[1] }
Legionella source: WATER (aerosolised). Cooling towers, hot water systems, spas/hot tubs, showers, decorative fountains, mist machines. Outbreaks: hotels, hospitals, cruise ships. Prevention: water system maintenance, temperature control (avoid 20-45°C — Legionella growth range), chlorination, copper-silver ionisation.[2] }
Mycoplasma: 'walking pneumonia' in young adults. Mild illness (patient 'walks around' with pneumonia). Dry cough, low fever, malaise. Chest X-ray: patchy infiltrates (often MORE extensive than clinical appearance suggests). Extrupulmonary: haemolysis (cold agglutinins), erythema multiforme, neurological (meningoencephalitis, Guillain-Barré), arthritis.[3] }
Mycoplasma cold agglutinins. Autoantibodies against RBC surface antigen (I) → agglutinate at low temperature → HAEMOLYTIC ANAEMIA (intravascular, cold exposure worsens). Positive in 50-70% of Mycoplasma. Detect: cold agglutinin titre (>1:64). Clinical: acrocyanosis (blue fingers/toes in cold), haemoglobinuria. Treatment: warm patient, treat Mycoplasma (azithromycin/doxycycline), transfusion if severe.[3] }
Chlamydia psittaci (psittacosis/ornithosis): bird exposure. Parrots, parakeets, pigeons, poultry. Inhalation of dried bird droppings. Clinical: dry cough, high fever, headache, splenomegaly, hepatitis (atypical pneumonia + systemic). Diagnosis: serology (4-fold rise in antibody titre). Treatment: doxycycline 100mg BD for 2-3 weeks. Mortality 20% if untreated.[8] }
Empiric atypical cover is recommended for ALL severe CAP (ATS/IDSA 2019). Beta-lactam + macrolide OR beta-lactam + fluoroquinolone. Even if atypical not confirmed. Rationale: Legionella can be severe (mortality 5-30%), atypicals not covered by beta-lactam alone, diagnostic delay (urine antigen may be negative early).[5] }
Levofloxacin is preferred for severe Legionella. Fluoroquinolones (levofloxacin 750mg IV OD, moxifloxacin 400mg IV OD) have BETTER intracellular penetration than macrolides → preferred for severe Legionnaires disease. Azithromycin 500mg IV OD is alternative (also effective). Duration: 7-14 days (longer if immunocompromised).[1] }
Legionella mortality: 5-30% (higher with delay, immunocompromise). Severe Legionella (ICU): mortality 15-30%. Risk factors for severe: age >50, smoker, chronic lung disease, immunosuppression (transplant, steroids). Early appropriate antibiotics (covering atypicals) REDUCE mortality.[2] }
Relative bradycardia in atypical pneumonia. Heart rate is LOWER than expected for degree of fever. Normal: fever 1°C → HR +10 bpm. In Legionella (and typhoid, leptospirosis): HR is lower than expected (e.g., fever 39.5°C, HR 80). Not always present, but suggests intracellular pathogen.[1] }
Mycoplasma PCR is now the diagnostic test of choice. Throat swab or sputum PCR (more sensitive than serology, available early). Serology (IgM, complement fixation) requires 4-fold rise (convalescent sample — 2-4 weeks). Cold agglutinins (non-specific). Culture: difficult (needs special media, slow growth). PCR available within hours.[3] }
Atypical pneumonia extrapulmonary complications. MYCOPLASMA: cold agglutinin haemolysis, Stevens-Johnson syndrome, Guillain-Barré, transverse myelitis, pericarditis, myocarditis, arthritis. LEGIONNA: SIADH, encephalopathy, renal failure, rhabdomyolysis. PSITTACOSIS: hepatitis, endocarditis, myocarditis. Always look for extrapulmonary manifestations.[3] }

Red flags

Prognosis

2019 ATS/IDSA CAP guidelines (Metlay 2019)

Updated guidelines for community-acquired pneumonia:

Empiric atypical cover: recommended for all severe CAP (beta-lactam + macrolide OR fluoroquinolone)
Routine atypical testing: NOT recommended (unless severe, outbreak, specific suspicion)
Legionella urine antigen: recommended in severe CAP (especially if SIADH, neurological, summer-fall)
Sputum culture: recommended for severe CAP, healthcare-associated risk factors [1]

Legionella mortality: 5-30% overall. Severe (ICU): 15-30%. Reduced with early appropriate antibiotics. Mycoplasma mortality: <1% (usually mild). Rare severe cases in elderly/immunocompromised. Psittacosis mortality: 1-5% treated, 20% untreated. Q fever mortality: 1-2% (higher with endocarditis — 25%).

[1]

Pathogen deep-dive

Mycoplasma pneumoniae — the #1 atypical pathogen

Mycoplasma pneumoniae is the COMMONEST atypical pathogen worldwide and the leading cause of community-acquired pneumonia (CAP) in older children and young adults (5-35 years). It is a cell-wall-deficient bacterium (smallest free-living organism, ~0.1-0.3 µm) — the absence of a cell wall explains BOTH why it is invisible on Gram stain AND why beta-lactams (which target peptidoglycan cross-linking) are useless. Only three drug classes work: macrolides (50S ribosome), tetracyclines (30S), and fluoroquinolones (DNA gyrase/topoisomerase IV). [1]

Classic presentation is 'walking pneumonia': an indolent illness (1-3 week prodrome) with dry cough, sore throat, low-grade fever, malaise and headache — the patient looks surprisingly well despite radiographic infiltrates that are often more extensive than the examination suggests. Chest X-ray typically shows patchy, unilateral, lower-lobe bronchopneumonia; pleural effusion is usually small when present. The white cell count is frequently normal or only mildly raised. [1]

Extrapulmonary disease is a hallmark and occurs in up to 25% — driven by immune-mediated mechanisms (molecular mimicry, autoantibodies) and direct organism spread: [1]

Haematological: cold agglutinin autoimmune haemolytic anaemia (IgM anti-I antibodies).
Dermatological: erythema multiforme, Stevens-Johnson syndrome (especially in children/young adults).
Neurological: aseptic meningitis, meningoencephalitis, transverse myelitis, cerebellar ataxia, Guillain-Barré syndrome (including the anti-GQ1b antibody variant).
Cardiac: pericarditis, myocarditis (rare but a leading cause of cardiovascular death in young patients with Mycoplasma).
Musculoskeletal: polyarthritis, myalgia.
Renal/ GI: glomerulonephritis, pancreatitis, hepatitis. [1]

Diagnosis: respiratory PCR (throat swab, nasopharyngeal aspirate or sputum) is now first-line — rapid, sensitive, and available early. Serology requires paired sera (4-fold rise in IgM/ complement-fixing antibody 2-4 weeks apart), so it confirms retrospectively. Cold agglutinin titre (>1:64) supports the diagnosis but is non-specific. Culture is slow and needs special media (Eaton's PPLO agar) — rarely performed.[3][6]

Legionella — the severe atypical

Legionella is a Gram-negative intracellular bacillus that thrives in warm aqueous environments (20-45°C). It causes a SPECTRUM: at one end the mild, self-limiting Pontiac fever (flu-like illness, no pneumonia, 95%+ attack rate, full recovery in ~1 week) and at the other Legionnaires' disease — a severe, sometimes fatal CAP that disproportionately reaches the ICU. Infection is by inhalation of contaminated water aerosols from cooling towers, evaporative condensers, spa pools/ hot tubs, showers, mist machines and decorative fountains; there is NO person-to-person spread. Risk factors for severe disease: age >50, smoking, chronic lung disease, immunosuppression (transplant, steroids, anti-TNF), and male sex.[1][2]

Clinical clues pointing to Legionnaires' disease (the "Winawer-Clancy" / Cunha constellation): high fever (>39°C), relative bradycardia, dry cough, prominent GI symptoms (diarrhoea, nausea, abdominal pain ~50%), neurological features (confusion, lethargy, headache ~30%), SIADH with hyponatraemia (Na <130), deranged liver enzymes, mild AKI and sometimes rhabdomyolysis. The chest X-ray classically shows a unilateral lower-lobe patchy consolidation that progresses rapidly and may cavitate (especially in the immunocompromised). Mortality ranges 5-10% in treated immunocompetent cases to 25-30% in ICU/ immunosuppressed patients.[1]

Diagnosis: the cornerstone is the Legionella urinary antigen test — a rapid (~1 hour), highly specific (>95%) immunochromatographic assay that detects soluble lipopolysaccharide antigen of L. pneumophila serogroup 1 (responsible for ~80-90% of community cases). Sensitivity ~70-90%; antigen is excreted from day 1 and persists for weeks, but the assay will MISS non-serogroup-1 and non-pneumophila species (e.g. L. longbeachae from potting mix — common in Australia/ New Zealand). Newer combined assays (e.g. ImmuView) detect both L. pneumophila sg1 and L. longbeachae. Confirm with respiratory PCR and culture on buffered charcoal yeast extract (BCYE) agar (3-10 days, allows molecular typing for outbreak investigation), and paired serology (4-fold rise).[10][2]

Chlamydia psittaci — psittacosis (ornithosis)

An obligate intracellular bacterium acquired by inhalation of aerosolised dried droppings, nasal secretions or feather dust from infected birds — psittacines (parrots, cockatiels, budgerigars), pigeons, poultry (turkeys, ducks), and poultry workers, bird breeders and pet-shop owners are at risk. Presents after a 5-14 day incubation with abrupt high fever, severe headache (often out of proportion), dry cough, myalgia, and a characteristic splenomegaly with a faint Horder's spots rash. Hepatitis (raised transaminases), myocarditis, endocarditis and encephalitis are recognised complications. Chest X-ray shows variable patchy consolidation. Diagnosis is by serology (4-fold rise in microimmunofluorescence antibody titre, or a single high IgM); PCR is increasingly available. Doxycycline 100 mg PO/IV BD for 2-3 weeks is the treatment of choice. Untreated mortality is ~20%; treated 1-5%. It is a NOTIFIABLE zoonosis in many jurisdictions.[8]

Chlamydia pneumoniae

A human-only (no animal reservoir) obligate intracellular pathogen transmitted person-to-person by respiratory droplets, with an incubation of 3-4 weeks. It is a common — and frequently under-recognised — cause of CAP, sinusitis, pharyngitis and bronchitis, and causes both endemic and epidemic disease in semi-closed populations (military recruits, university dormitories, nursing homes). Clinically it overlaps with Mycoplasma: prolonged dry cough, sore throat, hoarseness (laryngitis is prominent), headache and sinus tenderness. Severity is usually mild-moderate but can cause severe pneumonia in the elderly and immunocompromised. An intriguing epidemiological association exists between C. pneumoniae and atherosclerosis (organism detected in coronary plaques), though causality and a treatment benefit remain unproven. Diagnosis is serology (microimmunofluorescence) or PCR; treatment is a macrolide or doxycycline.[6]

Coxiella burnetii — Q fever

A Gram-negative obligate intracellular bacterium (formerly a rickettsia) with a remarkable spore-like small cell variant that resists desiccation and persists in the environment. The classic reservoirs are cattle, sheep and goats; birth products, faeces, urine and milk are heavily contaminated. Inhalation of infected dust (wind-borne spread — patients may NOT recall direct animal contact), or less often tick vectors or unpasteurised milk, transmits disease. Farmers, abattoir workers and veterinarians are at highest risk; it is a recognised bioterrorism agent (CDC category B). [1]

Q fever has two phases. Acute Q fever: incubation ~2-3 weeks, then high fever, severe headache, myalgia, and a mild atypical pneumonia (often only on imaging) OR a self-limiting granulomatous hepatitis (doughnut granulomas). Chronic Q fever (<5%, developing months-years later) is defined by infection lasting >6 months and most often manifests as culture-negative endocarditis of prosthetic or previously damaged valves — the leading cause of death; vascular infections (aneurysms) and chronic hepatitis also occur. Pregnancy raises the risk of chronic infection and obstetric complications. [1]

Diagnosis: serology with phase-variation antibodies is key — acute disease is dominated by phase II IgM (and rising phase II IgG), while chronic disease shows high-titre phase I IgG (≥1:800 is the diagnostic hallmark of endocarditis). PCR on blood/ tissue is useful early. Doxycycline 100 mg BD for 14 days treats acute disease; chronic Q fever needs doxycycline PLUS hydroxychloroquine for ≥18 months (hydroxychloroquine raises the phagolysosomal pH and overcomes Coxiella's intracellular alkalinisation defence). An effective whole-cell vaccine (Q-Vax) is available and recommended for high-risk occupational groups in Australia.[7]

[1]

Distinguishing atypical from typical pneumonia

Typical vs atypical pneumonia — bedside contrast

Feature	Typical (S. pneumoniae, H. influenzae)	Atypical (Mycoplasma, Legionella, Chlamydia, Coxiella)
Onset	Abrupt (hours), rigors	Gradual/ subacute (days-weeks)
Cough	Purulent (rusty sputum in pneumococcal)	Dry, hacking, scant sputum
Fever	High, shaking rigors	Moderate (Legionella high); relative bradycardia
Systemic	Localised to chest	Headache, myalgia, GI, neurological prominent
Examination	Focal crackles, consolidation signs	Often disproportionate — exam underestimates X-ray
Chest X-ray	Lobar consolidation	Patchy, interstitial, lower-lobe, bilateral
WCC	Leucocytosis (neutrophils)	Normal/ mildly raised
Gram stain	Neutrophils + organism	Neutrophils, NO organism seen
Beta-lactam response	Good within 48-72 h	NO response (need macrolide/ doxycycline/ fluoroquinolone)

[1]

Pontiac fever vs Legionnaires' disease (both Legionella)

Feature	Pontiac fever	Legionnaires' disease
Clinical syndrome	Acute self-limiting flu-like illness (NO pneumonia)	Severe pneumonia ± multi-organ
Attack rate	Very high (~90-95%)	Low (~5%) of those exposed
Incubation	5-66 hours (short)	2-10 days
Chest X-ray	Normal	Patchy/ lobar consolidation, progresses, may cavitate
Severity	Mild, no deaths	5-30% mortality
Treatment	Supportive only (antibiotics not required)	Fluoroquinolone or macrolide urgently
Host	Any age, healthy	Elderly, smokers, immunocompromised

[1]

Atypical-pathogen antibiotic comparison

Drug	Class	Dose (adult, severe)	Pros	Cons/ cautions
Azithromycin	Macrolide	500 mg IV OD	Excellent intracellular levels, short course, paediatric-suitable, QT-prolonging	Macrolide-resistant Mycoplasma in Asia
Clarithromycin	Macrolide	500 mg IV BD	Strong atypical cover	More drug interactions (CYP3A4), phlebitis
Doxycycline	Tetracycline	100 mg IV/PO BD	Cheap, oral bioavailability, covers all atypicals + rickettsiae/ Q fever	Photosensitivity, avoid <8 yr/ pregnancy, oesophagitis
Levofloxacin	Fluoroquinolone	750 mg IV/PO OD	First-line SEVERE Legionella, monotherapy covers typicals + atypicals	QT prolongation, tendinopathy, dysglycaemia, C. difficile
Moxifloxacin	Fluoroquinolone	400 mg IV/PO OD	Best pneumonia bioavailability, monotherapy	Same FQ risks; not for UTI

[1]

Diagnostic workup of suspected atypical pneumonia

Investigation pathway for suspected atypical CAP

Recognise the clinical pattern — dry cough + headache + myalgia + extrapulmonary features + beta-lactam failure → think atypical.
Send Legionella urinary antigen on admission — for ALL severe CAP (ATS/IDSA 2019), especially with SIADH, diarrhoea, confusion, summer-autumn onset. Use a combined assay (e.g. ImmuView) if L. longbeachae is plausible (ANZ).[5][10]
Respiratory PCR — nose/throat swab or sputum for Mycoplasma, Chlamydia (psittaci + pneumoniae), and Legionella multiplex. Most useful early, before antibiotics.[3]
Bloods — FBC (often normal WCC), U&E (hyponatraemia = SIADH in Legionella), LFTs (hepatitis in Legionella/ psittacosis/ Q fever), CK (rhabdomyolysis), troponin.
Cultures — sputum and blood cultures (rule in/ out typicals; Legionella needs BCYE agar). Do NOT rely on sputum Gram stain to exclude atypicals — they will not be seen.
Serology (paired) — acute AND convalescent (2-4 weeks) for Mycoplasma, Chlamydia psittaci, Coxiella (phase I/II), Chlamydia pneumoniae. Confirms retrospectively but is essential for public-health/ outbreak work.
Targeted history — birds (psittacosis), livestock/ parturient animals/ unpasteurised milk (Q fever), spa pools/ cooling towers/ travel (Legionella), sick contacts (Mycoplasma/ C. pneumoniae).
Chest imaging — CXR (patchy lower-lobe/ interstitial pattern); CT chest if CXR is mild but clinical picture severe or to define complications (cavitation, effusion, empyema, abscess).

ICU management of Legionnaires' disease

Empiric cover from the outset — severe CAP = beta-lactam (ceftriaxone 2 g IV OD) PLUS a Legionella-active agent. Do NOT wait for confirmation.[5]
Definitive therapy once suspected/ confirmed — levofloxacin 750 mg IV OD (preferred for severe disease) OR azithromycin 500 mg IV OD. Fluoroquinolones achieve higher intracellular alveolar macrophage concentrations and may shorten fever time vs macrolides.[1]
Duration — 7-14 days (7 days for levofloxacin in immunocompetent; 14-21 days if immunocompromised, cavitation or endocarditis).
Supportive care — lung-protective ventilation for ARDS, vasopressors for septic shock, fluid balance (caution — SIADH causes water retention; correct Na slowly), renal replacement therapy if rhabdomyolysis-induced AKI.
Search for and report the source — notify public health; environmental sampling of cooling towers/ water systems; molecular typing (sequence-based typing) to link clinical and environmental isolates.
Look for complications — empyema (drain), cavitation (prolong antibiotics), endocarditis (rare — culture-negative), pericarditis, neurological involvement.
De-escalate — stop the beta-lactam once Legionella is confirmed and typicals excluded.

Workup of suspected cold-agglutinin haemolytic anaemia (Mycoplasma)

Suspect — patient with atypical CAP + new pallor/ jaundice/ dark urine/ acrocyanosis (cold-exposed extremities), falling haemoglobin.
Bloods — FBC (anaemia), reticulocyte count (raised), unconjugated bilirubin ↑, LDH ↑, haptoglobin ↓ (haemolysis).
Direct antiglobulin test (DAT) — positive for C3d only (IgM fixes complement; IgG negative) — the cold antibody pattern.
Cold agglutinin titre — IgM anti-I autoantibody, active below body temperature; titre >1:64 (often >1:512) supports the diagnosis.
Confirm trigger — Mycoplasma PCR/ serology.
Management — KEEP THE PATIENT WARM (avoid cold exposure/ cold IV fluids), treat the Mycoplasma (azithromycin or doxycycline), supportive transfusion (blood warmer) for severe anaemia. Steroids/ rituximab reserved for severe refractory cases. Avoid splenectomy (ineffective — complement-mediated).[3]

Mnemonics and memory aids

WHY IS IT 'ATYPICAL'? — three defining features

[1]

LEGION — clinical clue cluster for Legionnaires' disease

More clinical pearls (extended)

Atypical pneumonia — second-set high-yield pearls for CICM/FFICM/EDIC

Mycoplasma is the #1 atypical pathogen worldwide. Leading cause of CAP in 5-35-year-olds; causes endemic disease with 3-7-year epidemic cycles (schools, military camps, dormitories). Most infections are subclinical or mild — the tip of the iceberg that reaches ICU is cold-agglutinin haemolysis, severe ARDS, or neuro/ cardiac complications.[3]
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a growing global problem. Driven by 23S rRNA mutations (A2063G most common). Rates are very high in China/ Japan/ Korea (often >70-90%), and rising in Europe/ North America/ Australia. Clinically: prolonged fever (>48-72 h on azithromycin) and worse radiographic/ clinical outcomes. Switch to doxycycline or a fluoroquinolone (levofloxacin) if MRMP is suspected or locally prevalent — but do NOT abandon macrolides wholesale, as they retain some immunomodulatory benefit.[9]
Pontiac fever is the mild face of Legionella. A self-limiting flu-like illness (fever, myalgia, headache) WITHOUT pneumonia, attack rate ~95%, no deaths, incubation 5-66 h. NO antibiotics needed — supportive care only. Important conceptually: it shows that the SAME organism can cause non-pneumonic (Pontiac) and pneumonic (Legionnaires') disease depending on host and inoculum.[2]
Legionella longbeachae — the ANZ exception to the urine antigen rule. Found in potting mix/ compost, common in Australia/ New Zealand, and NOT detected by the standard (serogroup-1 pneumophila) urinary antigen. Use a combined assay (ImmuView) or respiratory PCR. Gardeners are the at-risk group — wear gloves and a mask, open potting mix outdoors, and avoid creating dust.[10]
Chlamydia pneumoniae is human-only and transmitted person-to-person. Unlike psittaci (birds) it has no animal reservoir — outbreaks occur in semi-closed populations (military recruits, university dorms, nursing homes). Think of it when "Mycoplasma-like" illness has prominent hoarseness/ laryngitis and sinusitis. Treatment: macrolide or doxycycline.[6]
Q fever — phase I vs phase II antibody tells you acute vs chronic. Acute disease: phase II IgM (and rising phase II IgG) predominate. Chronic disease (endocarditis): high-titre phase I IgG ≥1:800 is the diagnostic hallmark. This phase-variation serology is a favourite exam question — phase I antibodies are made against the virulent, smooth-LPS (chronic) form.[7]
Chronic Q fever endocarditis is culture-negative and insidious. Suspect in any "culture-negative endocarditis" with a prosthetic/ previously damaged valve, especially in a farmer/ vet/ abattoir worker. Vegetations may be small. Treat with doxycycline + hydroxychloroquine for ≥18 months — hydroxychloroquine alkalinises the phagolysosome, defeating Coxiella's acid-dependent intracellular survival. Monitor serology (phase I IgG titre fall) and valve surveillance.[7]
Psittacosis — the bird exposure is often MISSED. Always ask about parrots, cockatiels, pigeons, poultry and pet-shop work in any undifferentiated CAP with severe headache + splenomegaly + hepatitis. Even brief, apparently trivial exposure (cleaning a bird cage, visiting a pet store) can transmit. Notifiable disease; doxycycline 2-3 weeks.[8]
Relative bradycardia is a clue to an intracellular pathogen. The pulse fails to rise appropriately for the fever (rule of thumb: expect ~10 bpm rise per 1°C above 37°C). Suggests Legionella, but also typhoid, leptospirosis, rickettsial disease, and (paradoxically) beta-blocker therapy — exclude the drug cause first.[1]
Why beta-lactams fail — match the drug to the target. Beta-lactams bind penicillin-binding proteins to cross-link peptidoglycan. Mycoplasma has NO cell wall (no peptidoglycan at all); Legionella, Chlamydia and Coxiella are obligate/ facultative intracellular — beta-lactams penetrate poorly into host cells. Effective agents reach the ribosome (macrolides, tetracyclines) or intracellular DNA (fluoroquinolones). This mechanistic point is exam gold.[4]
Chest X-ray often 'looks worse than the patient' in Mycoplasma. A young adult with mild symptoms but extensive bilateral patchy infiltrates is classic. Conversely, in Legionella the X-ray often looks deceptively focal early, then progresses and may cavitate (especially in the immunocompromised) — re-image if clinically deteriorating.[3]
Empiric atypical cover is MANDATORY in severe CAP. ATS/IDSA 2019: beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone. Monotherapy with a respiratory fluoroquinolone (moxifloxacin/ levofloxacin) is acceptable for non-severe CAP and covers both typicals and atypicals. NEVER treat severe CAP with a beta-lactam alone.[5]
Steroids as adjuncts in severe atypical pneumonia — selective use. Evidence is strongest for adjunct steroids in severe pneumococcal pneumonia (conflicting data) and in refractory Mycoplasma pneumoniae pneumonia with cytokine storm (especially in MRMP). No routine role for Legionella/ Q fever. Use case-by-case, not as a blanket.[9]
Q fever in pregnancy is high-risk. Can cause abortion, stillbirth, intrauterine growth restriction and predisposes to chronic maternal infection. Treat with co-trimoxazole throughout pregnancy (doxycycline is contraindicated — fetal bone/ tooth effects), then switch to doxycycline + hydroxychloroquine post-partum if chronic infection is confirmed. Screen with serology.[7]
Vaccination and prevention. No routine vaccines for Mycoplasma, Chlamydia or Legionella. Q fever vaccine (Q-Vax) — effective whole-cell vaccine, recommended pre-exposure for high-risk occupational groups (abattoir workers, farmers, vets, laboratory staff) in Australia; requires pre-vaccination serology and skin test (severe local reactions if given to previously exposed). Legionella prevention = engineering controls on water systems (temperature 60°C at source, biocides, copper-silver ionisation, avoidance of 20-45°C dead-legs).[2][7]
Public-health notification and outbreak investigation. Legionnaires' disease, psittacosis and Q fever are all notifiable in Australia/ NZ and the UK. A single case of Legionella triggers source investigation (cooling-tower registers, spa-pool logs, travel history); clusters warrant molecular typing (sequence-based typing/ MLVA) to link cases to environmental isolates. ICUs should have a low threshold to involve public health.[2]

Extended red flags

Atypical pneumonia — extended red flags and pitfalls

Macrolide non-response in Mycoplasma (persistent fever >72 h on azithromycin) — switch to doxycycline/ levofloxacin; suspect macrolide resistance (MRMP), especially if Asia-exposed.[9]
Culture-negative endocarditis in a farmer/ vet — chronic Q fever (Coxiella); send phase I IgG.[7]
Negative urine antigen does NOT exclude Legionella — misses non-serogroup-1 and L. longbeachae; send PCR/ serology if suspicion persists.[10]
Young adult with severe CAP + haemolysis — Mycoplasma cold agglutinin disease; keep warm, treat organism, transfuse via blood-warmer.[3]
Cavitation on chest imaging in 'atypical' pneumonia — think Legionella (immunocompromised), severe psittacosis, or Q fever; not classical for Mycoplasma.[1]
Pregnant patient with Q fever — high risk of obstetric loss + chronic infection; use co-trimoxazole, NOT doxycycline.[7]
Hoarseness + sinusitis + atypical pneumonia — Chlamydia pneumoniae (human-to-human); distinguish from psittaci (bird) on history.[6]
Spa pool/ hot tub exposure + pneumonia — Legionella (even domestic spas); also consider hot-tub lung (hypersensitivity pneumonitis from Mycobacterium avium complex) — very different management.[2]

Evidence and prognosis (extended)

Macrolide-resistant Mycoplasma pneumoniae — the emerging threat (Wang 2024 expert consensus)

Mechanism: point mutations in domain V of the 23S rRNA gene (A2063G most common, also A2064G) reduce ribosomal macrolide binding — high-level resistance.
Epidemiology: rates >70-90% in mainland China, ~50-90% in Japan/ Korea, <10-25% in Europe/ North America/ Australia but rising.
Clinical impact: prolonged fever, longer hospital stay, more radiographic progression — but macrolides retain modest immunomodulatory activity and mortality remains low.
Management: if MRMP suspected (failure to defervesce in 48-72 h, endemic region), switch to doxycycline or minocycline, or a fluoroquinolone (levofloxacin, moxifloxacin — avoid in children where possible due to tendon/ cartilage concerns). Tetracyclines are increasingly first-line in high-prevalence regions.
Stewardship message: do not abandon macrolides wholesale — they remain first-line where resistance is low, and tetracyclines/ fluoroquinolones carry their own age/ toxicity constraints.[9]

Q fever (Coxiella burnetii) — acute vs chronic management (España 2020)

Acute Q fever: doxycycline 100 mg BD for 14 days is first-line. In pregnancy use co-trimoxazole throughout. Mild disease may recover without antibiotics, but treatment reduces progression to chronic infection.
Chronic Q fever: defined by infection >6 months. Endocarditis, vascular infection, chronic hepatitis, osteomyelitis. Treat with doxycycline + hydroxychloroquine ≥18 months (hydroxychloroquine overcomes Coxiella's intracellular alkalinisation). Monitor phase I IgG titre and clinical/ valve status.
Patients at risk of chronicity (prolong/ intensify follow-up + consider extended primary therapy): pre-existing valvulopathy, prosthetic valve, vascular graft, pregnancy, immunosuppression.
Serology landmarks: acute = phase II IgM/ rising phase II IgG; chronic = phase I IgG ≥1:800.[7]

2019 ATS/IDSA CAP guideline — atypical-relevant changes (Metlay 2019)

Empiric atypicals: for severe (ICU) CAP, beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone — atypical cover is now EXPECTED, not optional.
Routine atypical testing: NOT recommended for all CAP — reserve Legionella urinary antigen and atypical PCR for SEVERE disease, outbreak settings, or specific clinical suspicion (SIADH, travel, animal exposure).
Sputum culture: recommended for severe CAP and where MRSA/ Pseudomonas risk factors exist.
Corticosteroids: NOT routinely recommended for CAP (possible benefit in severe disease but harm in influenza — must test for influenza first).
Healthcare-associated pneumonia (HCAP) category removed — replaced by local validation of risk factors for resistant organisms.[5]

Severity and prognosis — at-a-glance

Atypical pneumonia — severity, duration and prognosis

Pathogen	Severity	ICU?	Antibiotic duration	Untreated mortality	Treated mortality
Legionella pneumophila	Most severe (the ICU atypical)	Often	7-14 d (levo) / up to 21 d immunocompromised	20-30%+	5-10% (15-30% ICU)
Mycoplasma pneumoniae	Usually mild	Rare (haemolysis, ARDS, neuro)	5-7 d (azithro) / 7-14 d doxy	<1% (rare severe)	<1%
Chlamydia psittaci	Variable	Sometimes	2-3 wk doxycycline	~20%	1-5%
Chlamydia pneumoniae	Mild-moderate	Rare	5-7 d azithro / 7-14 d doxy	low	low
Coxiella burnetii (acute)	Mild-moderate	Rare	14 d doxycycline	low (self-limiting)	<1%
Coxiella burnetii (chronic)	Severe (endocarditis)	Yes (sepsis/ heart failure)	≥18 mo doxy + hydroxychloroquine	high	5-25%

[1] [1]

References

[1]Cunha BA, et al. Legionnaire's Disease and its Mimics: A Clinical Perspective Infect Dis Clin North Am, 2017.PMID 28159179
[2]Phin N, et al. Epidemiology and clinical management of Legionnaires' disease Lancet Infect Dis, 2014.PMID 24970283
[3]Waites KB, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond Clin Microbiol Rev, 2017.PMID 28539503
[4]Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis, 2007.PMID 17278083
[5]Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
[6]Miyashita N, et al. Atypical pneumonia: Pathophysiology, diagnosis, and treatment Respir Investig, 2022.PMID 34750083
[7]España PP, et al. Q Fever (Coxiella Burnetii) Semin Respir Crit Care Med, 2020.PMID 32629489
[8]Beeckman DS, et al. Zoonotic Chlamydophila psittaci infections from a clinical perspective Clin Microbiol Infect, 2009.PMID 19220335
[9]Wang YS, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children World J Pediatr, 2024.PMID 39143259
[10]Badoux P, et al. Method Comparison of the ImmuView L. pneumophila and L. longbeachae Urinary Antigen Test with the BinaxNOW Legionella Urinary Antigen Card for Detection of Legionella pneumophila Serogroup 1 Antigen in Urine J Clin Microbiol, 2020.PMID 31826962

[1]

Atypical pneumonia pathogens

Feature	Legionella pneumophila	Mycoplasma pneumoniae	Chlamydia psittaci	Coxiella burnetii
Severity	SEVERE (ICU common)	Mild-moderate ('walking pneumonia')	Variable	Usually mild (Q fever)
Source	Water (cooling towers, spas, showers)	Person-to-person (droplet)	Birds (parrots, pigeons — psittacosis)	Animals (cattle, sheep — Q fever)
Age	>50, smokers, immunocompromised	Young adults (5-20)	Bird owners, pet shop workers	Farmers, veterinarians
Clinical clues	GI (diarrhoea, nausea), neurological (confusion), SIADH/hyponatraemia, relative bradycardia, high fever	Dry cough, prominent extrapulmonary (haemolysis, rash, neurological, arthritis)	Dry cough, headache, splenomegaly, hepatitis	Fever, hepatitis, endocarditis
Diagnosis	Urine antigen (L. pneumophila serogroup 1), PCR, serology	PCR (throat), serology	Serology (4-fold rise)	Serology
Treatment	Levofloxacin OR azithromycin	Azithromycin OR doxycycline	Doxycycline	Doxycycline
Mortality	5-30% (higher if untreated)	<1%	1-5% (untreated 20%)	1-2%

[1]

Empiric antibiotic strategy for severe CAP (covering atypicals)

Severe CAP (ICU) — cover BOTH typical (S. pneumoniae) AND atypical pathogens
Beta-lactam + macrolide: ceftriaxone 2g IV OD + azithromycin 500mg IV OD (PREFERRED — covers typicals + atypicals)
OR Beta-lactam + fluoroquinolone: ceftriaxone + levofloxacin/moxifloxacin (if macrolide allergy)
OR fluoroquinolone monotherapy (moxifloxacin) — covers both typicals + atypicals (for non-severe only)
Add atypical cover EARLY — beta-lactams ALONE do NOT cover atypicals (Legionella, Mycoplasma, Chlamydia)
Narrow when pathogen identified — if Legionella confirmed: levofloxacin or azithromycin monotherapy
Duration: 5-7 days (CAP), 7-14 days (Legionella — longer, immunocompromised)

[1]

SAQ — Legionnaires\u2019 disease in severe community-acquired pneumonia

10 minutes · 10 marks

[1]

SAQ — Mycoplasma cold-agglutinin haemolytic anaemia

10 minutes · 10 marks

[1]

Clinical pearls

High-yield atypical pneumonia points for CICM/FFICM exam

'Atypical' pathogens are NOT seen on Gram stain and do NOT grow on standard culture. Legionella (intracellular, needs buffered charcoal yeast extract — BCYE agar), Mycoplasma (cell wall-deficient, needs special media), Chlamydia (intracellular). You CANNOT diagnose from sputum Gram stain. Need: urine antigen (Legionella), PCR, serology.[4] }
Beta-lactams do NOT cover atypicals. Atypicals lack typical cell wall (Mycoplasma) or are intracellular (Legionella, Chlamydia) → beta-lactams (which target cell wall synthesis) INEFFECTIVE. Need: macrolides, tetracyclines, or fluoroquinolones (which act intracellularly or on ribosomes). If CAP not responding to beta-lactam → add atypical cover.[4] }
Legionella urine antigen is the rapid diagnostic test. Detects L. pneumophila SEROGROUP 1 (causes 80-90% of Legionnaires disease). Result within hours. HIGH specificity (>95%), moderate sensitivity (70-90%). Limitation: only detects serogroup 1 (other serogroups need PCR/serology). Urine can be sent from day 1.[1] }
Legionella clinical clues ('Winawer-Clancy criteria'). (1) GI symptoms (diarrhoea, nausea, vomiting — 50%). (2) Neurological (confusion, headache — 30%). (3) SIADH (hyponatraemia — Na <130). (4) Relative bradycardia (pulse slower than expected for fever). (5) High fever (>39°C). (6) NO sputum production (dry cough). (7) Beta-lactam failure. If several present → think Legionella.[1] }
Legionella source: WATER (aerosolised). Cooling towers, hot water systems, spas/hot tubs, showers, decorative fountains, mist machines. Outbreaks: hotels, hospitals, cruise ships. Prevention: water system maintenance, temperature control (avoid 20-45°C — Legionella growth range), chlorination, copper-silver ionisation.[2] }
Mycoplasma: 'walking pneumonia' in young adults. Mild illness (patient 'walks around' with pneumonia). Dry cough, low fever, malaise. Chest X-ray: patchy infiltrates (often MORE extensive than clinical appearance suggests). Extrupulmonary: haemolysis (cold agglutinins), erythema multiforme, neurological (meningoencephalitis, Guillain-Barré), arthritis.[3] }
Mycoplasma cold agglutinins. Autoantibodies against RBC surface antigen (I) → agglutinate at low temperature → HAEMOLYTIC ANAEMIA (intravascular, cold exposure worsens). Positive in 50-70% of Mycoplasma. Detect: cold agglutinin titre (>1:64). Clinical: acrocyanosis (blue fingers/toes in cold), haemoglobinuria. Treatment: warm patient, treat Mycoplasma (azithromycin/doxycycline), transfusion if severe.[3] }
Chlamydia psittaci (psittacosis/ornithosis): bird exposure. Parrots, parakeets, pigeons, poultry. Inhalation of dried bird droppings. Clinical: dry cough, high fever, headache, splenomegaly, hepatitis (atypical pneumonia + systemic). Diagnosis: serology (4-fold rise in antibody titre). Treatment: doxycycline 100mg BD for 2-3 weeks. Mortality 20% if untreated.[8] }
Empiric atypical cover is recommended for ALL severe CAP (ATS/IDSA 2019). Beta-lactam + macrolide OR beta-lactam + fluoroquinolone. Even if atypical not confirmed. Rationale: Legionella can be severe (mortality 5-30%), atypicals not covered by beta-lactam alone, diagnostic delay (urine antigen may be negative early).[5] }
Levofloxacin is preferred for severe Legionella. Fluoroquinolones (levofloxacin 750mg IV OD, moxifloxacin 400mg IV OD) have BETTER intracellular penetration than macrolides → preferred for severe Legionnaires disease. Azithromycin 500mg IV OD is alternative (also effective). Duration: 7-14 days (longer if immunocompromised).[1] }
Legionella mortality: 5-30% (higher with delay, immunocompromise). Severe Legionella (ICU): mortality 15-30%. Risk factors for severe: age >50, smoker, chronic lung disease, immunosuppression (transplant, steroids). Early appropriate antibiotics (covering atypicals) REDUCE mortality.[2] }
Relative bradycardia in atypical pneumonia. Heart rate is LOWER than expected for degree of fever. Normal: fever 1°C → HR +10 bpm. In Legionella (and typhoid, leptospirosis): HR is lower than expected (e.g., fever 39.5°C, HR 80). Not always present, but suggests intracellular pathogen.[1] }
Mycoplasma PCR is now the diagnostic test of choice. Throat swab or sputum PCR (more sensitive than serology, available early). Serology (IgM, complement fixation) requires 4-fold rise (convalescent sample — 2-4 weeks). Cold agglutinins (non-specific). Culture: difficult (needs special media, slow growth). PCR available within hours.[3] }
Atypical pneumonia extrapulmonary complications. MYCOPLASMA: cold agglutinin haemolysis, Stevens-Johnson syndrome, Guillain-Barré, transverse myelitis, pericarditis, myocarditis, arthritis. LEGIONNA: SIADH, encephalopathy, renal failure, rhabdomyolysis. PSITTACOSIS: hepatitis, endocarditis, myocarditis. Always look for extrapulmonary manifestations.[3] }

Red flags

Prognosis

2019 ATS/IDSA CAP guidelines (Metlay 2019)

Updated guidelines for community-acquired pneumonia:

Empiric atypical cover: recommended for all severe CAP (beta-lactam + macrolide OR fluoroquinolone)
Routine atypical testing: NOT recommended (unless severe, outbreak, specific suspicion)
Legionella urine antigen: recommended in severe CAP (especially if SIADH, neurological, summer-fall)
Sputum culture: recommended for severe CAP, healthcare-associated risk factors [1]

[1]

Pathogen deep-dive

Mycoplasma pneumoniae — the #1 atypical pathogen

Extrapulmonary disease is a hallmark and occurs in up to 25% — driven by immune-mediated mechanisms (molecular mimicry, autoantibodies) and direct organism spread: [1]

Haematological: cold agglutinin autoimmune haemolytic anaemia (IgM anti-I antibodies).
Dermatological: erythema multiforme, Stevens-Johnson syndrome (especially in children/young adults).
Neurological: aseptic meningitis, meningoencephalitis, transverse myelitis, cerebellar ataxia, Guillain-Barré syndrome (including the anti-GQ1b antibody variant).
Cardiac: pericarditis, myocarditis (rare but a leading cause of cardiovascular death in young patients with Mycoplasma).
Musculoskeletal: polyarthritis, myalgia.
Renal/ GI: glomerulonephritis, pancreatitis, hepatitis. [1]

Legionella — the severe atypical

Chlamydia psittaci — psittacosis (ornithosis)

Chlamydia pneumoniae

Coxiella burnetii — Q fever

[1]

Distinguishing atypical from typical pneumonia

Typical vs atypical pneumonia — bedside contrast

Feature	Typical (S. pneumoniae, H. influenzae)	Atypical (Mycoplasma, Legionella, Chlamydia, Coxiella)
Onset	Abrupt (hours), rigors	Gradual/ subacute (days-weeks)
Cough	Purulent (rusty sputum in pneumococcal)	Dry, hacking, scant sputum
Fever	High, shaking rigors	Moderate (Legionella high); relative bradycardia
Systemic	Localised to chest	Headache, myalgia, GI, neurological prominent
Examination	Focal crackles, consolidation signs	Often disproportionate — exam underestimates X-ray
Chest X-ray	Lobar consolidation	Patchy, interstitial, lower-lobe, bilateral
WCC	Leucocytosis (neutrophils)	Normal/ mildly raised
Gram stain	Neutrophils + organism	Neutrophils, NO organism seen
Beta-lactam response	Good within 48-72 h	NO response (need macrolide/ doxycycline/ fluoroquinolone)

[1]

Pontiac fever vs Legionnaires' disease (both Legionella)

Feature	Pontiac fever	Legionnaires' disease
Clinical syndrome	Acute self-limiting flu-like illness (NO pneumonia)	Severe pneumonia ± multi-organ
Attack rate	Very high (~90-95%)	Low (~5%) of those exposed
Incubation	5-66 hours (short)	2-10 days
Chest X-ray	Normal	Patchy/ lobar consolidation, progresses, may cavitate
Severity	Mild, no deaths	5-30% mortality
Treatment	Supportive only (antibiotics not required)	Fluoroquinolone or macrolide urgently
Host	Any age, healthy	Elderly, smokers, immunocompromised

[1]

Atypical-pathogen antibiotic comparison

Drug	Class	Dose (adult, severe)	Pros	Cons/ cautions
Azithromycin	Macrolide	500 mg IV OD	Excellent intracellular levels, short course, paediatric-suitable, QT-prolonging	Macrolide-resistant Mycoplasma in Asia
Clarithromycin	Macrolide	500 mg IV BD	Strong atypical cover	More drug interactions (CYP3A4), phlebitis
Doxycycline	Tetracycline	100 mg IV/PO BD	Cheap, oral bioavailability, covers all atypicals + rickettsiae/ Q fever	Photosensitivity, avoid <8 yr/ pregnancy, oesophagitis
Levofloxacin	Fluoroquinolone	750 mg IV/PO OD	First-line SEVERE Legionella, monotherapy covers typicals + atypicals	QT prolongation, tendinopathy, dysglycaemia, C. difficile
Moxifloxacin	Fluoroquinolone	400 mg IV/PO OD	Best pneumonia bioavailability, monotherapy	Same FQ risks; not for UTI

[1]

Diagnostic workup of suspected atypical pneumonia

Investigation pathway for suspected atypical CAP

Recognise the clinical pattern — dry cough + headache + myalgia + extrapulmonary features + beta-lactam failure → think atypical.
Send Legionella urinary antigen on admission — for ALL severe CAP (ATS/IDSA 2019), especially with SIADH, diarrhoea, confusion, summer-autumn onset. Use a combined assay (e.g. ImmuView) if L. longbeachae is plausible (ANZ).[5][10]
Respiratory PCR — nose/throat swab or sputum for Mycoplasma, Chlamydia (psittaci + pneumoniae), and Legionella multiplex. Most useful early, before antibiotics.[3]
Bloods — FBC (often normal WCC), U&E (hyponatraemia = SIADH in Legionella), LFTs (hepatitis in Legionella/ psittacosis/ Q fever), CK (rhabdomyolysis), troponin.
Cultures — sputum and blood cultures (rule in/ out typicals; Legionella needs BCYE agar). Do NOT rely on sputum Gram stain to exclude atypicals — they will not be seen.
Serology (paired) — acute AND convalescent (2-4 weeks) for Mycoplasma, Chlamydia psittaci, Coxiella (phase I/II), Chlamydia pneumoniae. Confirms retrospectively but is essential for public-health/ outbreak work.
Targeted history — birds (psittacosis), livestock/ parturient animals/ unpasteurised milk (Q fever), spa pools/ cooling towers/ travel (Legionella), sick contacts (Mycoplasma/ C. pneumoniae).
Chest imaging — CXR (patchy lower-lobe/ interstitial pattern); CT chest if CXR is mild but clinical picture severe or to define complications (cavitation, effusion, empyema, abscess).

ICU management of Legionnaires' disease

Empiric cover from the outset — severe CAP = beta-lactam (ceftriaxone 2 g IV OD) PLUS a Legionella-active agent. Do NOT wait for confirmation.[5]
Definitive therapy once suspected/ confirmed — levofloxacin 750 mg IV OD (preferred for severe disease) OR azithromycin 500 mg IV OD. Fluoroquinolones achieve higher intracellular alveolar macrophage concentrations and may shorten fever time vs macrolides.[1]
Duration — 7-14 days (7 days for levofloxacin in immunocompetent; 14-21 days if immunocompromised, cavitation or endocarditis).
Supportive care — lung-protective ventilation for ARDS, vasopressors for septic shock, fluid balance (caution — SIADH causes water retention; correct Na slowly), renal replacement therapy if rhabdomyolysis-induced AKI.
Search for and report the source — notify public health; environmental sampling of cooling towers/ water systems; molecular typing (sequence-based typing) to link clinical and environmental isolates.
Look for complications — empyema (drain), cavitation (prolong antibiotics), endocarditis (rare — culture-negative), pericarditis, neurological involvement.
De-escalate — stop the beta-lactam once Legionella is confirmed and typicals excluded.

Workup of suspected cold-agglutinin haemolytic anaemia (Mycoplasma)

Suspect — patient with atypical CAP + new pallor/ jaundice/ dark urine/ acrocyanosis (cold-exposed extremities), falling haemoglobin.
Bloods — FBC (anaemia), reticulocyte count (raised), unconjugated bilirubin ↑, LDH ↑, haptoglobin ↓ (haemolysis).
Direct antiglobulin test (DAT) — positive for C3d only (IgM fixes complement; IgG negative) — the cold antibody pattern.
Cold agglutinin titre — IgM anti-I autoantibody, active below body temperature; titre >1:64 (often >1:512) supports the diagnosis.
Confirm trigger — Mycoplasma PCR/ serology.
Management — KEEP THE PATIENT WARM (avoid cold exposure/ cold IV fluids), treat the Mycoplasma (azithromycin or doxycycline), supportive transfusion (blood warmer) for severe anaemia. Steroids/ rituximab reserved for severe refractory cases. Avoid splenectomy (ineffective — complement-mediated).[3]

Mnemonics and memory aids

WHY IS IT 'ATYPICAL'? — three defining features

[1]

LEGION — clinical clue cluster for Legionnaires' disease

More clinical pearls (extended)

Atypical pneumonia — second-set high-yield pearls for CICM/FFICM/EDIC

Mycoplasma is the #1 atypical pathogen worldwide. Leading cause of CAP in 5-35-year-olds; causes endemic disease with 3-7-year epidemic cycles (schools, military camps, dormitories). Most infections are subclinical or mild — the tip of the iceberg that reaches ICU is cold-agglutinin haemolysis, severe ARDS, or neuro/ cardiac complications.[3]
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a growing global problem. Driven by 23S rRNA mutations (A2063G most common). Rates are very high in China/ Japan/ Korea (often >70-90%), and rising in Europe/ North America/ Australia. Clinically: prolonged fever (>48-72 h on azithromycin) and worse radiographic/ clinical outcomes. Switch to doxycycline or a fluoroquinolone (levofloxacin) if MRMP is suspected or locally prevalent — but do NOT abandon macrolides wholesale, as they retain some immunomodulatory benefit.[9]
Pontiac fever is the mild face of Legionella. A self-limiting flu-like illness (fever, myalgia, headache) WITHOUT pneumonia, attack rate ~95%, no deaths, incubation 5-66 h. NO antibiotics needed — supportive care only. Important conceptually: it shows that the SAME organism can cause non-pneumonic (Pontiac) and pneumonic (Legionnaires') disease depending on host and inoculum.[2]
Legionella longbeachae — the ANZ exception to the urine antigen rule. Found in potting mix/ compost, common in Australia/ New Zealand, and NOT detected by the standard (serogroup-1 pneumophila) urinary antigen. Use a combined assay (ImmuView) or respiratory PCR. Gardeners are the at-risk group — wear gloves and a mask, open potting mix outdoors, and avoid creating dust.[10]
Chlamydia pneumoniae is human-only and transmitted person-to-person. Unlike psittaci (birds) it has no animal reservoir — outbreaks occur in semi-closed populations (military recruits, university dorms, nursing homes). Think of it when "Mycoplasma-like" illness has prominent hoarseness/ laryngitis and sinusitis. Treatment: macrolide or doxycycline.[6]
Q fever — phase I vs phase II antibody tells you acute vs chronic. Acute disease: phase II IgM (and rising phase II IgG) predominate. Chronic disease (endocarditis): high-titre phase I IgG ≥1:800 is the diagnostic hallmark. This phase-variation serology is a favourite exam question — phase I antibodies are made against the virulent, smooth-LPS (chronic) form.[7]
Chronic Q fever endocarditis is culture-negative and insidious. Suspect in any "culture-negative endocarditis" with a prosthetic/ previously damaged valve, especially in a farmer/ vet/ abattoir worker. Vegetations may be small. Treat with doxycycline + hydroxychloroquine for ≥18 months — hydroxychloroquine alkalinises the phagolysosome, defeating Coxiella's acid-dependent intracellular survival. Monitor serology (phase I IgG titre fall) and valve surveillance.[7]
Psittacosis — the bird exposure is often MISSED. Always ask about parrots, cockatiels, pigeons, poultry and pet-shop work in any undifferentiated CAP with severe headache + splenomegaly + hepatitis. Even brief, apparently trivial exposure (cleaning a bird cage, visiting a pet store) can transmit. Notifiable disease; doxycycline 2-3 weeks.[8]
Relative bradycardia is a clue to an intracellular pathogen. The pulse fails to rise appropriately for the fever (rule of thumb: expect ~10 bpm rise per 1°C above 37°C). Suggests Legionella, but also typhoid, leptospirosis, rickettsial disease, and (paradoxically) beta-blocker therapy — exclude the drug cause first.[1]
Why beta-lactams fail — match the drug to the target. Beta-lactams bind penicillin-binding proteins to cross-link peptidoglycan. Mycoplasma has NO cell wall (no peptidoglycan at all); Legionella, Chlamydia and Coxiella are obligate/ facultative intracellular — beta-lactams penetrate poorly into host cells. Effective agents reach the ribosome (macrolides, tetracyclines) or intracellular DNA (fluoroquinolones). This mechanistic point is exam gold.[4]
Chest X-ray often 'looks worse than the patient' in Mycoplasma. A young adult with mild symptoms but extensive bilateral patchy infiltrates is classic. Conversely, in Legionella the X-ray often looks deceptively focal early, then progresses and may cavitate (especially in the immunocompromised) — re-image if clinically deteriorating.[3]
Empiric atypical cover is MANDATORY in severe CAP. ATS/IDSA 2019: beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone. Monotherapy with a respiratory fluoroquinolone (moxifloxacin/ levofloxacin) is acceptable for non-severe CAP and covers both typicals and atypicals. NEVER treat severe CAP with a beta-lactam alone.[5]
Steroids as adjuncts in severe atypical pneumonia — selective use. Evidence is strongest for adjunct steroids in severe pneumococcal pneumonia (conflicting data) and in refractory Mycoplasma pneumoniae pneumonia with cytokine storm (especially in MRMP). No routine role for Legionella/ Q fever. Use case-by-case, not as a blanket.[9]
Q fever in pregnancy is high-risk. Can cause abortion, stillbirth, intrauterine growth restriction and predisposes to chronic maternal infection. Treat with co-trimoxazole throughout pregnancy (doxycycline is contraindicated — fetal bone/ tooth effects), then switch to doxycycline + hydroxychloroquine post-partum if chronic infection is confirmed. Screen with serology.[7]
Vaccination and prevention. No routine vaccines for Mycoplasma, Chlamydia or Legionella. Q fever vaccine (Q-Vax) — effective whole-cell vaccine, recommended pre-exposure for high-risk occupational groups (abattoir workers, farmers, vets, laboratory staff) in Australia; requires pre-vaccination serology and skin test (severe local reactions if given to previously exposed). Legionella prevention = engineering controls on water systems (temperature 60°C at source, biocides, copper-silver ionisation, avoidance of 20-45°C dead-legs).[2][7]
Public-health notification and outbreak investigation. Legionnaires' disease, psittacosis and Q fever are all notifiable in Australia/ NZ and the UK. A single case of Legionella triggers source investigation (cooling-tower registers, spa-pool logs, travel history); clusters warrant molecular typing (sequence-based typing/ MLVA) to link cases to environmental isolates. ICUs should have a low threshold to involve public health.[2]

Extended red flags

Atypical pneumonia — extended red flags and pitfalls

Macrolide non-response in Mycoplasma (persistent fever >72 h on azithromycin) — switch to doxycycline/ levofloxacin; suspect macrolide resistance (MRMP), especially if Asia-exposed.[9]
Culture-negative endocarditis in a farmer/ vet — chronic Q fever (Coxiella); send phase I IgG.[7]
Negative urine antigen does NOT exclude Legionella — misses non-serogroup-1 and L. longbeachae; send PCR/ serology if suspicion persists.[10]
Young adult with severe CAP + haemolysis — Mycoplasma cold agglutinin disease; keep warm, treat organism, transfuse via blood-warmer.[3]
Cavitation on chest imaging in 'atypical' pneumonia — think Legionella (immunocompromised), severe psittacosis, or Q fever; not classical for Mycoplasma.[1]
Pregnant patient with Q fever — high risk of obstetric loss + chronic infection; use co-trimoxazole, NOT doxycycline.[7]
Hoarseness + sinusitis + atypical pneumonia — Chlamydia pneumoniae (human-to-human); distinguish from psittaci (bird) on history.[6]
Spa pool/ hot tub exposure + pneumonia — Legionella (even domestic spas); also consider hot-tub lung (hypersensitivity pneumonitis from Mycobacterium avium complex) — very different management.[2]

Evidence and prognosis (extended)

Macrolide-resistant Mycoplasma pneumoniae — the emerging threat (Wang 2024 expert consensus)

Mechanism: point mutations in domain V of the 23S rRNA gene (A2063G most common, also A2064G) reduce ribosomal macrolide binding — high-level resistance.
Epidemiology: rates >70-90% in mainland China, ~50-90% in Japan/ Korea, <10-25% in Europe/ North America/ Australia but rising.
Clinical impact: prolonged fever, longer hospital stay, more radiographic progression — but macrolides retain modest immunomodulatory activity and mortality remains low.
Management: if MRMP suspected (failure to defervesce in 48-72 h, endemic region), switch to doxycycline or minocycline, or a fluoroquinolone (levofloxacin, moxifloxacin — avoid in children where possible due to tendon/ cartilage concerns). Tetracyclines are increasingly first-line in high-prevalence regions.
Stewardship message: do not abandon macrolides wholesale — they remain first-line where resistance is low, and tetracyclines/ fluoroquinolones carry their own age/ toxicity constraints.[9]

Q fever (Coxiella burnetii) — acute vs chronic management (España 2020)

Acute Q fever: doxycycline 100 mg BD for 14 days is first-line. In pregnancy use co-trimoxazole throughout. Mild disease may recover without antibiotics, but treatment reduces progression to chronic infection.
Chronic Q fever: defined by infection >6 months. Endocarditis, vascular infection, chronic hepatitis, osteomyelitis. Treat with doxycycline + hydroxychloroquine ≥18 months (hydroxychloroquine overcomes Coxiella's intracellular alkalinisation). Monitor phase I IgG titre and clinical/ valve status.
Patients at risk of chronicity (prolong/ intensify follow-up + consider extended primary therapy): pre-existing valvulopathy, prosthetic valve, vascular graft, pregnancy, immunosuppression.
Serology landmarks: acute = phase II IgM/ rising phase II IgG; chronic = phase I IgG ≥1:800.[7]

2019 ATS/IDSA CAP guideline — atypical-relevant changes (Metlay 2019)

Empiric atypicals: for severe (ICU) CAP, beta-lactam + macrolide OR beta-lactam + respiratory fluoroquinolone — atypical cover is now EXPECTED, not optional.
Routine atypical testing: NOT recommended for all CAP — reserve Legionella urinary antigen and atypical PCR for SEVERE disease, outbreak settings, or specific clinical suspicion (SIADH, travel, animal exposure).
Sputum culture: recommended for severe CAP and where MRSA/ Pseudomonas risk factors exist.
Corticosteroids: NOT routinely recommended for CAP (possible benefit in severe disease but harm in influenza — must test for influenza first).
Healthcare-associated pneumonia (HCAP) category removed — replaced by local validation of risk factors for resistant organisms.[5]

Severity and prognosis — at-a-glance

Atypical pneumonia — severity, duration and prognosis

Pathogen	Severity	ICU?	Antibiotic duration	Untreated mortality	Treated mortality
Legionella pneumophila	Most severe (the ICU atypical)	Often	7-14 d (levo) / up to 21 d immunocompromised	20-30%+	5-10% (15-30% ICU)
Mycoplasma pneumoniae	Usually mild	Rare (haemolysis, ARDS, neuro)	5-7 d (azithro) / 7-14 d doxy	<1% (rare severe)	<1%
Chlamydia psittaci	Variable	Sometimes	2-3 wk doxycycline	~20%	1-5%
Chlamydia pneumoniae	Mild-moderate	Rare	5-7 d azithro / 7-14 d doxy	low	low
Coxiella burnetii (acute)	Mild-moderate	Rare	14 d doxycycline	low (self-limiting)	<1%
Coxiella burnetii (chronic)	Severe (endocarditis)	Yes (sepsis/ heart failure)	≥18 mo doxy + hydroxychloroquine	high	5-25%

[1] [1]

References

[1]Cunha BA, et al. Legionnaire's Disease and its Mimics: A Clinical Perspective Infect Dis Clin North Am, 2017.PMID 28159179
[2]Phin N, et al. Epidemiology and clinical management of Legionnaires' disease Lancet Infect Dis, 2014.PMID 24970283
[3]Waites KB, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond Clin Microbiol Rev, 2017.PMID 28539503
[4]Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis, 2007.PMID 17278083
[5]Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
[6]Miyashita N, et al. Atypical pneumonia: Pathophysiology, diagnosis, and treatment Respir Investig, 2022.PMID 34750083
[7]España PP, et al. Q Fever (Coxiella Burnetii) Semin Respir Crit Care Med, 2020.PMID 32629489
[8]Beeckman DS, et al. Zoonotic Chlamydophila psittaci infections from a clinical perspective Clin Microbiol Infect, 2009.PMID 19220335
[9]Wang YS, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children World J Pediatr, 2024.PMID 39143259
[10]Badoux P, et al. Method Comparison of the ImmuView L. pneumophila and L. longbeachae Urinary Antigen Test with the BinaxNOW Legionella Urinary Antigen Card for Detection of Legionella pneumophila Serogroup 1 Antigen in Urine J Clin Microbiol, 2020.PMID 31826962